Markolf Hanefeld

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Activities & Behaviors

Fasting

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Hanefeld Markolf; Bornstein Stefan R; Pistrosch Frank
Shifting the disease management paradigm from glucose: what are the cons?
Koutnikova Hana; Laakso Markku; Lu Lu; Combe Roy; Paananen Jussi; Kuulasmaa Teemu; Kuusisto Johanna; Häring Hans-Ulrich; Hansen Torben; Pedersen Oluf; Smith Ulf; Hanefeld Markolf; Williams Robert W; Auwerx Johan
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.
Hanefeld M
The role of pioglitazone in modifying the atherogenic lipoprotein profile.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Markolf Hanefeld (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Hanefeld Markolf; Bornstein Stefan R; Pistrosch Frank
Shifting the disease management paradigm from glucose: what are the cons?
Diabetes care 2009;32 Suppl 2():S353-6.
2009: Koutnikova Hana; Laakso Markku; Lu Lu; Combe Roy; Paananen Jussi; Kuulasmaa Teemu; Kuusisto Johanna; Häring Hans-Ulrich; Hansen Torben; Pedersen Oluf; Smith Ulf; Hanefeld Markolf; Williams Robert W; Auwerx Johan
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.
PLoS genetics 2009;5(8):e1000591.
2009: Hanefeld M
The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Diabetes, obesity & metabolism 2009;11(8):742-56.
2009: Home Philip D; Pocock Stuart J; Beck-Nielsen Henning; Curtis Paula S; Gomis Ramon; Hanefeld Markolf; Jones Nigel P; Komajda Michel; McMurray John J V;
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet 2009;373(9681):2125-35.
2009: Thomas Andreas; Schönauer Martin; Achermann Frank; Schnell Oliver; Hanefeld Markolf; Ziegelasch Hans-Jürgen; Mastrototaro John; Heinemann Lutz
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.
Diabetes technology & therapeutics 2009;11(6):399-409.
2009: Pfützner A; Schöndorf T; Hanefeld M; Lübben G; Kann P H; Karagiannis E; Wilhelm B; Forst T
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(3):202-6.
2009: Schwarz Peter E H; Li Jiang; Reimann Manja; Schutte Alta E; Bergmann Antje; Hanefeld Markolf; Bornstein Stefan R; Schulze Jan; Tuomilehto Jaakko; Lindström Jaana
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2009;94(3):920-6.
2009: Schwarz P E H; Bornstein S R; Hanefeld M
The future of the metabolic syndrome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(2):73-4.
2009: Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein S R; Hanefeld M
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(2):104-8.
2009: Temelkova-Kurktschiev Theodora S; Kurktschiev Dimo P; Vladimirova-Kitova Lyudmila G; Koehler Carsta; Henkel Elena; Todorova Boryana R; Schaper Frank; Fuecker Katya; Hanefeld Markolf
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies.
Folia medica 2009;51(1):34-41.
2009: Hanefeld Markolf; Karasik Avraham; Koehler Carsta; Westermeier Torsten; Chiasson Jean-Louis
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2009;6(1):32-7.
2009: Pfützner Andreas; Efstrathios Karagiannis; Löbig Mirjam; Armbruster Franz Paul; Hanefeld Markolf; Forst Thomas
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.
Clinical laboratory 2009;55(7-8):275-81.
2009: Ansquer Jean-Claude; Bekaert Ivan; Guy Martine; Hanefeld Markolf; Simon Alain;
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2009;9(2):91-101.
2008: Forst Thomas; Wilhelm Birgit; Pfützner Andreas; Fuchs Winfried; Lehmann Ute; Schaper Frank; Weber Matthias; Müller Jürgen; Konrad Thomas; Hanefeld Markolf
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2008;5(4):298-303.
2008: Leonhardt Wolfgang; Pfützner Andreas; Müller Jürgen; Pietzsch Jens; Forst Thomas; Karagiannis Efstrathios; Lübben Georg; Hanefeld Markolf
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Atherosclerosis 2008;201(1):155-62.
2008: Bergmann A; Li J; Reimann M; Hentrich T; Hanefeld M; Bornstein S R; Schwarz P E H
Polymorphisms in perilipin gene (PLIN) are not associated with obesity and weight variation in people with high risk of type 2 diabetes.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2008;116 Suppl 1():S56-8.
2008: Hanefeld Markolf; Schaper Frank; Koehler Carsta
Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(3):225-31.
2008: Rothe Ulrike; Müller Gabriele; Schwarz Peter E H; Seifert Martin; Kunath Hildebrand; Koch Rainer; Bergmann Sybille; Julius Ulrich; Bornstein Stefan R; Hanefeld Markolf; Schulze Jan
Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research.
Diabetes care 2008;31(5):863-8.
2008: Mohler Emile R; Ballantyne Christie M; Davidson Michael H; Hanefeld Markolf; Ruilope Luis M; Johnson Joel L; Zalewski Andrew;
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Journal of the American College of Cardiology 2008;51(17):1632-41.
2008: Hanefeld Markolf; Schaper Frank
Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Expert review of cardiovascular therapy 2008;6(2):153-63.
2008: Milicevic Zvonko; Raz Itamar; Beattie Scott D; Campaigne Barbara N; Sarwat Samiha; Gromniak Elwira; Kowalska Irina; Galic Edvard; Tan Meng; Hanefeld Markolf
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
Diabetes care 2008;31 Suppl 2():S155-60.
2008: Komajda Michel; Curtis Paula; Hanefeld Markolf; Beck-Nielsen Henning; Pocock Stuart J; Zambanini Andrew; Jones Nigel P; Gomis Ramon; Home Philip D;
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Cardiovascular diabetology 2008;7():10.
2007: Hanefeld Markolf
Is rosiglitazone associated with increased risk for cardiovascular events?
Nature clinical practice. Cardiovascular medicine 2007;4(12):648-9.
2007: Pfützner A; Hanefeld M; Lübben G; Weber M M; Karagiannis E; Köhler C; Hohberg C; Forst T
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(10):764-8.
2007: Home Philip D; Pocock Stuart J; Beck-Nielsen Henning; Gomis Ramón; Hanefeld Markolf; Jones Nigel P; Komajda Michel; McMurray John J V;
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
The New England journal of medicine 2007;357(1):28-38.
2007: Schwarz Peter E H; Bornstein Stefan R; Hanefeld Markolf
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.
Diabetes research and clinical practice 2007;77(1):148-50.
2007: Hanefeld M
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
International journal of clinical practice. Supplement 2007;(153):20-7.
2007: Hanefeld Markolf; Herman Gary A; Wu Mei; Mickel Carolyn; Sanchez Matilde; Stein Peter P;
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Current medical research and opinion 2007;23(6):1329-39.
2007: Home P D; Jones N P; Pocock S J; Beck-Nielsen H; Gomis R; Hanefeld M; Komajda M; Curtis P;
Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(6):626-34.
2007: Henkel Elena; Gallo Sarsta; Siegert Gilvina; Koehler Cabriele; Hanefeld Markolf
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(4):327-34.
2007: Pistrosch Frank; Reissmann Eva; Wildbrett Jan; Koehler Carsta; Hanefeld Markolf
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients.
American journal of hypertension 2007;20(5):541-5.
2007: Forst Thomas; Pfützner Andreas; Lübben Georg; Weber Matthias; Marx Nikolaus; Karagiannis Efstrathios; Koehler Carsta; Baurecht Werner; Hohberg Cloth; Hanefeld Markolf
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
Metabolism: clinical and experimental 2007;56(4):491-6.
2007: Hanefeld M; Schaper F; Ceriello A
[History and definition(s) of metabolic syndrome]
Der Internist 2007;48(2):117-25.
2007: Hanefeld Markolf; Marx Nikolaus; Pfützner Andreas; Baurecht Werner; Lübben Georg; Karagiannis Efstrathios; Stier Ulf; Forst Thomas
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Journal of the American College of Cardiology 2007;49(3):290-7.
2007: Monnier Louis; Colette Claude; Leiter Lawrence; Ceriello Antonio; Hanefeld Markolf; Owens David; Tajima Naoko; Tuomiletho Jaakko; Davidson Jaime;
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
Diabetes care 2007;30(1):185-6; author reply 187-8.
2007: Hanefeld Markolf; Patwardhan Rita; Jones Nigel P;
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2007;17(1):13-23.
2007: Hanefeld Markolf
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Cardiovascular diabetology 2007;6():20.
2007: Hanefeld Markolf; Koehler Carsta; Gallo Silvina; Benke Inge; Ott Petra
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study.
Cardiovascular diabetology 2007;6():13.
2006: Hanefeld M
[The metabolic syndrome: where are we going and for what benefits?]
Deutsche medizinische Wochenschrift (1946) 2006;131 Suppl 8():S236-9.
2006: Ceriello Antonio; Davidson Jamie; Hanefeld Markolf; Leiter Lawrence; Monnier Louis; Owens David; Tajima Naoko; Tuomilehto Jaakko;
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2006;16(7):453-6.
2006: Pistrosch F; Koehler C; Wildbrett J; Hanefeld M
Relationship between diurnal glucose levels and HbA1c in type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(7):455-9.
2006: Schwarz Peter E H; Towers Gordon W; Fischer Sabine; Govindarajalu Suresh; Schulze Jan; Bornstein Stephan R; Hanefeld Markolf; Vasseur Francis
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter.
Diabetes care 2006;29(7):1645-50.
2006: Hanefeld M; Pfützner A; Forst T; Lübben G
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Current medical research and opinion 2006;22(6):1211-5.
2006: Hanefeld Markolf; Metzler Wolfgang; Köhler Carsta; Schaper Frank
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]
Herz 2006;31(3):246-54; quiz 255.
2006: Kazda Christof; Hülstrunk Hiltrud; Helsberg Karin; Langer Frank; Forst Thomas; Hanefeld Markolf
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Journal of diabetes and its complications 2006;20(3):145-52.
2006: Hanefeld Markolf
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2006;12 Suppl 1():56-9.
2005: Hanefeld Markolf; Schaper Frank
Prandial hyperglycemia: is it important to track and treat?
Current diabetes reports 2005;5(5):333-9.
2005: Henkel Elena; Menschikowski Mario; Koehler Carsta; Leonhardt Wolfgang; Hanefeld Markolf
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Metabolism: clinical and experimental 2005;54(9):1168-73.
2005: Hanefeld Markolf
Introduction: new approaches to managing diabetic dyslipidaemia.
Atherosclerosis. Supplements 2005;6(3):1-2.
2005: Home P D; Pocock S J; Beck-Nielsen H; Gomis R; Hanefeld M; Dargie H; Komajda M; Gubb J; Biswas N; Jones N P
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Diabetologia 2005;48(9):1726-35.
2005: Hanefeld Markolf; Josse Robert G; Chiasson Jean-Louis
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al.
Diabetes care 2005;28(7):1840; author reply 1841.
2005: Ceriello A; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J
To: Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS (2004) The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. Diabetologia 47:1838-1846.
Diabetologia 2005;48(7):1423-4; author reply 1425-6.
2005: Charbonnel B H; Matthews D R; Schernthaner G; Hanefeld M; Brunetti P;
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(4):399-405.
2005: Matthews D R; Charbonnel B H; Hanefeld M; Brunetti P; Schernthaner G
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Diabetes/metabolism research and reviews 2005;21(2):167-74.
2005: Hanefeld M
[Glucose-independent impact of the glitazones on the cardiovascular outcome]
MMW Fortschritte der Medizin 2005;147(1-2):37-9.
2005: Leiter Lawrence A; Ceriello Antonio; Davidson Jaime A; Hanefeld Markolf; Monnier Louis; Owens David R; Tajima Naoko; Tuomilehto Jaakko;
Postprandial glucose regulation: new data and new implications.
Clinical therapeutics 2005;27 Suppl B():S42-56.
2005: Hanefeld M
Outcome studies in type 2 diabetes.
Current medical research and opinion 2005;21 Suppl 1():S41-8.
2004: Ceriello Antonio; Hanefeld Markolf; Leiter Lawrence; Monnier Louis; Moses Alan; Owens David; Tajima Naoko; Tuomilehto Jaakko
Postprandial glucose regulation and diabetic complications.
Archives of internal medicine 2004;164(19):2090-5.
2004: Hanefeld M; Köhler C
[Screening, prevention and early therapy of type 2 diabetics]
MMW Fortschritte der Medizin 2004;146(35-36):28-9, 31.
2004: Temelkova-Kurktschiev Theodora; Hanefeld Markolf; Chinetti Giulia; Zawadzki Christophe; Haulon Stephan; Kubaszek Agata; Koehler Carsta; Leonhardt Wolfgang; Staels Bart; Laakso Markku
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.
The Journal of clinical endocrinology and metabolism 2004;89(9):4238-42.
2004: Hanefeld Markolf; Schaper Frank
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]
Herz 2004;29(5):480-7.
2004: Chiasson J-L; Josse R G; Gomis R; Hanefeld M; Karasik A; Laakso M;
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Diabetologia 2004;47(6):969-75; discussion 976-7.
2004: Karrei Katharina; Koehler Carsta; Hanefeld Markolf; Temelkova-Kurktschiev Theodora; Del Prato Stefano
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2004;1(1):51-2.
2004: Hanefeld Markolf; Chiasson Jean Louis; Koehler Carsta; Henkel Elena; Schaper Frank; Temelkova-Kurktschiev Theodora
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Stroke; a journal of cerebral circulation 2004;35(5):1073-8.
2004: Temelkova-Kurktschiev T; Hanefeld M
The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2004;112(2):75-9.
2004: Pistrosch Frank; Passauer Jens; Fischer Sabine; Fuecker Katja; Hanefeld Markolf; Gross Peter
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Diabetes care 2004;27(2):484-90.
2004: Hanefeld Markolf; Brunetti Paolo; Schernthaner Guntram H; Matthews David R; Charbonnel Bernard H;
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Diabetes care 2004;27(1):141-7.
2004: Hanefeld M; Cagatay M; Petrowitsch T; Neuser D; Petzinna D; Rupp M
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
European heart journal 2004;25(1):10-6.
2003: Metzler W; Fücker K; Schwanebeck U; Hanefeld M; Julius U; Kindel B; Fischer S
[Significance of triglycerides for other metabolic parameters in the familial metabolic syndrome]
Deutsche medizinische Wochenschrift (1946) 2003;128(38):1941-6.
2003: Chiasson Jean-Louis; Josse Robert G; Gomis Ramon; Hanefeld Markolf; Karasik Avraham; Laakso Markku;
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA : the journal of the American Medical Association 2003;290(4):486-94.
2003: Hanefeld Markolf; Koehler Carsta; Fuecker Katja; Henkel Elena; Schaper Frank; Temelkova-Kurktschiev Theodora;
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.
Diabetes care 2003;26(3):868-74.
2003: Hanefeld M; Fischer S
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]
MMW Fortschritte der Medizin 2003;145(9):30-4.
2003: Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Diabetes, obesity & metabolism 2003;5(1):38-44.
2002: Hanefeld M; Sachse G
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
Diabetes, obesity & metabolism 2002;4(6):415-23.
2002: Temelkova-Kurktschiev Theodora; Koehler Carsta; Henkel Elena; Hanefeld Markolf
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.
Cardiovascular research 2002;56(2):277-83.
2002: Hanefeld Markolf
[In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]
MMW Fortschritte der Medizin 2002;144(40):12.
2002: Kopprasch Steffi; Pietzsch Jens; Kuhlisch Eberhard; Fuecker Katja; Temelkova-Kurktschiev Theodora; Hanefeld Markolf; Kühne Helmut; Julius Ulrich; Graessler Jürgen
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance.
Diabetes 2002;51(10):3102-6.
2002: Fischer S; Hanefeld M; Haffner S M; Fusch C; Schwanebeck U; Köhler C; Fücker K; Julius U
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass.
Acta diabetologica 2002;39(3):105-10.
2002: Hanefeld M; Fischer S
[Differential type 2 diabetes therapy based on pathophysiological aspects]
Therapeutische Umschau. Revue thérapeutique 2002;59(8):393-401.
2002: Hanefeld Markolf
Postprandial hyperglycaemia: noxious effects on the vessel wall.
International journal of clinical practice. Supplement 2002;(129):45-50.
2002: Chiasson Jean-Louis; Josse Robert G; Gomis Ramon; Hanefeld Markolf; Karasik Avraham; Laakso Markku;
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet 2002;359(9323):2072-7.
2002: Kaiser M; Temelkova-Kurktschiev T; Hanefeld M
Intima-media thickness and atherosclerotic plaques in familial defective apolipoprotein B-100 and familial hypercholesterolemia.
Annals of the New York Academy of Sciences 2002;967():528-34.
2002: Temelkova-Kurktschiev T; Siegert G; Bergmann S; Henkel E; Koehler C; Jaross W; Hanefeld M
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.
Metabolism: clinical and experimental 2002;51(6):743-9.
2002: Henkel E; Köhler C; Temelkova-Kurktschiev T; Hanefeld M
[Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study]
Deutsche medizinische Wochenschrift (1946) 2002;127(18):953-7.
2002: Hanefeld M; Temelkova-Kurktschiev T
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2002;12(2):98-107.
2002: Henkel E; Temelkova-Kurktschiev Th; Koehler C; Pietzsch J; Leonhardt W; Hanefeld M
Impaired glucose tolerance is not associated with lipid intolerance.
Diabetes, nutrition & metabolism 2002;15(2):84-90.
2002: Hanefeld Markolf; Köhler Carsta
[The metabolic syndrome and its epidemiologic dimensions in historical perspective]
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2002;96(3):183-8.
2002: Hanefeld M; Haffner S M; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Diabetes research and clinical practice 2002;55(3):221-7.
2002: Temelkova-Kurktschiev T; Henkel E; Koehler C; Karrei K; Hanefeld M
Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance.
Diabetologia 2002;45(1):151.
2002: Temelkova-Kurktschiev Theodora S; Hanefeld Markolf
Oral glucose tolerance test: to be or not to be performed?
Clinical laboratory 2002;48(3-4):143-52.
2001: Henkel E; Hanefeld M
[Hyperlipidemia and fibrates with special reference to diabetes]
Herz 2001;26(8):523-30.
2001: Hanefeld M; Belcher G
Safety profile of pioglitazone.
International journal of clinical practice. Supplement 2001;(121):27-31.
2001: Hanefeld M
Pharmacokinetics and clinical efficacy of pioglitazone.
International journal of clinical practice. Supplement 2001;(121):19-25.
2001: Hanefeld M
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?]
MMW Fortschritte der Medizin 2001;143(21):38-42.
2001: Temelkova-Kurktschiev T; Henkel E; Koehler C; Hanefeld M
Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD study.
Atherosclerosis 2001;156(1):239-40.
2001: Temelkova-Kurktschiev T; Fischer S; Koehler C; Mennicken G; Henkel E; Hanefeld M
[Intima-media thickness in healthy probands without risk factors for arteriosclerosis]
Deutsche medizinische Wochenschrift (1946) 2001;126(8):193-7.
2000: Hanefeld M; Koehler C; Henkel E; Fuecker K; Schaper F; Temelkova-Kurktschiev T
Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2000;17(12):835-40.
2000: Temelkova-Kurktschiev T S; Koehler C; Henkel E; Leonhardt W; Fuecker K; Hanefeld M
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.
Diabetes care 2000;23(12):1830-4.
2000: Hanefeld M
Post-prandial hyperglycaemia and vascular disease.
International journal of clinical practice. Supplement 2000;(112):13-8.
2000: Noack B; Jachmann I; Roscher S; Sieber L; Kopprasch S; Lück C; Hanefeld M; Hoffmann T
Metabolic diseases and their possible link to risk indicators of periodontitis.
Journal of periodontology 2000;71(6):898-903.
2000: Hanefeld M; Bouter K P; Dickinson S; Guitard C
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Diabetes care 2000;23(2):202-7.
2000: Pixa A; Pietzsch J; Julius U; Menschikowski M; Hanefeld M
Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism.
Amino acids 2000;18(3):289-98.
2000: Temelkova-Kurktschiev T; Henkel E; Schaper F; Koehler C; Siegert G; Hanefeld M
Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil?
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2000;108(2):93-9.
1999: Pietzsch J; Julius U; Hanefeld M
Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance.
Annals of the New York Academy of Sciences 1999;892():323-6.
1999: Pietzsch J; Julius U; Kirch C; Fischer S; Hanefeld M
Very low density lipoprotein overproduction is maximally expressed in early insulin resistant states.
Annals of the New York Academy of Sciences 1999;892():319-22.
1999: Gehrisch S; Kostka H; Tiebel M; Patzak A; Paetzold A; Julius U; Schroeder H E; Hanefeld M; Jaross W
Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia.
Journal of molecular medicine (Berlin, Germany) 1999;77(10):728-34.
1999: Köhler C; Temelkova-Kurktschiev T; Schaper F; Fücker K; Hanefeld M
[Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes]
Deutsche medizinische Wochenschrift (1946) 1999;124(37):1057-61.
1999: Hanefeld M; Koehler C; Schaper F; Fuecker K; Henkel E; Temelkova-Kurktschiev T
Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.
Atherosclerosis 1999;144(1):229-35.
1999: Leonhardt W; Hanefeld M; Schaper F
Diminished susceptibility to in vitro oxidation of low-density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content.
Atherosclerosis 1999;144(1):103-7.
1999: Koehler C; Temelkova-Kurktschiev T; Henkel E; Schaper F; Fuecker K; Hanefeld M
Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one?
Diabetologia 1999;42(5):635-6.
1999: Hanefeld M; Temelkova-Kurktschiev T; Schaper F; Henkel E; Siegert G; Koehler C
Impaired fasting glucose is not a risk factor for atherosclerosis.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(3):212-8.
1999: Wildbrett J; Nagel M; Theissig F; Gaertner H J; Gromeier S; Fischer S; Hanefeld M
[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity]
Deutsche medizinische Wochenschrift (1946) 1999;124(9):248-52.
1999: Temelkova-Kurktschiev T S; Koehler C; Leonhardt W; Schaper F; Henkel E; Siegert G; Hanefeld M
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.
Diabetes care 1999;22(2):333-8.
1999: Breidert M; Haroske G; Gromeier S; Dziambor U; Hanefeld M
[Bone pain in the last pregnancy trimester]
Der Internist 1999;40(1):100-4.
1999: Leonhardt W; Horn R; Brabant G; Breidert M; Temelkova-Kurktschiev T; Fücker K; Hanefeld M
Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT).
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1999;107(1):46-52.
1998: Pietzsch J; Julius U; Nitzsche S; Hanefeld M
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Diabetes 1998;47(12):1928-34.
1998: Chiasson J L; Gomis R; Hanefeld M; Josse R G; Karasik A; Laakso M
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Diabetes care 1998;21(10):1720-5.
1998: Hanefeld M; Temelkova-Kurktschiev T
Commercially sponsored supplements.
Diabetic medicine : a journal of the British Diabetic Association 1998;15(8):707-8.
1998: Hanefeld M
The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.
Journal of diabetes and its complications 1998;12(4):228-37.
1998: Temelkova-Kurktschiev T; Koehler C; Schaper F; Henkel E; Hahnefeld A; Fuecker K; Siegert G; Hanefeld M
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.
Diabetologia 1998;41(6):706-12.
1998: Banz K; Dinkel R; Hanefeld M; Schwanebeck U
Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision-analytical approach.
PharmacoEconomics 1998;13(4):449-59.
1998: Fischer S; Hanefeld M; Spengler M; Boehme K; Temelkova-Kurktschiev T
European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
Acta diabetologica 1998;35(1):34-40.
1998: Breidert M; Temelkova-Kurktschiev T; Hanefeld M; Leonhardt W; Schmoeckel A; Seissler J
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106(2):113-6.
1997: Temelkova-Kurktschiev T; Hanefeld M; Leonhardt W
Small dense low-density lipoprotein (LDL) in non-insulin-dependent diabetes mellitus (NIDDM). Impact of hypertriglyceridemia.
Annals of the New York Academy of Sciences 1997;827():279-86.
1997: Hanefeld M; Temelkova-Kurktschiev T; Köhler C
Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin-dependent diabetes mellitus.
Annals of the New York Academy of Sciences 1997;827():246-68.
1997: Hanefeld M; Temelkova-Kurktschiev T
The postprandial state and the risk of atherosclerosis.
Diabetic medicine : a journal of the British Diabetic Association 1997;14 Suppl 3():S6-11.
1997: Hanefeld M; Schmechel H; Schwanebeck U; Lindner J
Predictors of coronary heart disease and death in NIDDM: the Diabetes Intervention Study experience.
Diabetologia 1997;40 Suppl 2():S123-4.
1997: Wildbrett J; Hanefeld M; Fücker K; Pinzer T; Bergmann S; Siegert G; Breidert M
Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1997;105(6):331-5.
1997: Pietzsch J; Julius U; Hanefeld M
Stable isotope ratio analysis of amino acids: the use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry.
Rapid communications in mass spectrometry : RCM 1997;11(17):1835-8.
1996: Hanefeld M; Fischer S
[Rational therapy of Type II diabetes]
Therapeutische Umschau. Revue thérapeutique 1996;53(12):914-24.
1996: Hanefeld M; Fischer S; Julius U; Schulze J; Schwanebeck U; Schmechel H; Ziegelasch H J; Lindner J
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.
Diabetologia 1996;39(12):1577-83.
1996: Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach.
Journal of lipid research 1996;37(10):2074-87.
1996: Leonhardt W; Hanefeld M; Müller G; Hora C; Meissner D; Lattke P; Paetzold A; Jaross W; Schroeder H E
Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects.
Clinica chimica acta; international journal of clinical chemistry 1996;254(2):173-86.
1996: Julius U; Hanefeld M
[Integrated drug therapy of the metabolic syndrome]
Der Internist 1996;37(7):722-30.
1996: Hanefeld M; Willms B
[Diagnosis of the metabolic syndrome]
Der Internist 1996;37(7):705-11.
1996: Hanefeld M; Schmechel H; Julius U; Schwanebeck U
Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study.
Diabetes research and clinical practice 1996;30 Suppl():67-70.
1995: Breidert M; Pinzer T; Wildbrett J; Bornstein S R; Hanefeld M
Long-term effect of octreotide in acromegaly on insulin resistance.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1995;27(5):226-30.
1995: Pietzsch J; Subat S; Nitzsche S; Leonhardt W; Schentke K U; Hanefeld M
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition.
Biochimica et biophysica acta 1995;1254(1):77-88.
1994: Leonhardt W; Pietzsch J; Julius U; Hanefeld M
Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrations.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1994;32(12):929-33.
1994: Leonhardt W; Hanefeld M; Fischer S; Schulze J
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
European journal of clinical investigation 1994;24 Suppl 3():45-9.
1994: Julius U; Fritsch H; Fritsch W; Rehak E; Fücker K; Leonhardt W; Hanefeld M
Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women.
The Clinical investigator 1994;72(7):502-7.
1992: Julius U; Hora C; Gross P; Fücker K; Bergmann S; Hanefeld M
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]
Fortschritte der Medizin 1992;110(35-36):669-72.
1992: Lindner J; Schmechel H; Hanefeld M; Schwanebeck U; Bauch K
[Coronary heart disease and insulin concentration in type II diabetic patients--results of a diabetes intervention study]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1992;47(6):246-50.
1991: Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Diabetes care 1991;14(8):732-7.
1991: Hanefeld M; Fischer S; Schmechel H; Rothe G; Schulze J; Dude H; Schwanebeck U; Julius U
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.
Diabetes care 1991;14(4):308-17.
1990: Fischer S; Hanefeld M; Lang P D; Fücker K; Bergmann S; Gehrisch S; Leonhardt W; Jaross W
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
Arzneimittel-Forschung 1990;40(4):469-72.
1989: Julius U; Leonardt W; Noack D; Schulze J; Nikulcheva N G; Jaross W; Hanefeld M
Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridaemia.
Experimental and clinical endocrinology 1989;94(1-2):187-93.
1989: Schmechel H; Schulze J; Hanefeld M; Lippold C; Schwanebeck U; Rössger G; Haller H
[Coronary heart diseases and associated risk factors in newly manifested type II diabetic patients over the course of 5 years]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1989;44(6):172-5.
1989: Hanefeld M; Weck M
Very low calorie diet therapy in obese non-insulin dependent diabetes patients.
International journal of obesity 1989;13 Suppl 2():33-7.
1989: Weck M; Hanefeld M; Schollberg K
Effects of VLCD in obese NIDDM (non-insulin dependent diabetes) on glucose, insulin and C-peptide dynamics.
International journal of obesity 1989;13 Suppl 2():159-60.
1988: Hanefeld M; Lang P D; Fischer S; Leonhardt W; Bergmann S; Jaross W
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
Arzneimittel-Forschung 1988;38(12):1835-7.
1988: Schmechel H; Schulze J; Hanefeld M; Julius U; Schwanebeck U; Lippold C
[The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1988;43(23):669-74.
1988: Beitz J; Schollberg K; Fischer S; Jaross W; Hanefeld M; Mest H J
Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL?
Biomedica biochimica acta 1988;47(2):181-7.
1987: Weck M; Fischer S; Hanefeld M; Leonhardt W; Julius U; Gräser W; Schneider B; Haller H
Loss of fat, water, and protein during very low calorie diets and complete starvation.
Klinische Wochenschrift 1987;65(23):1142-50.
1987: Leonhardt W; Hanefeld M; Julius U; Schulze J; Fischer S; Weck M; Haller H
Predictive value of the index of desirable body weight for total body fat mass as measured by dilution of tritiated water--problems and limitations.
International journal of obesity 1987;11(3):221-8.
1986: Schmechel H; Fischer S; Lippold C; Schulze J; Hanefeld M; Haller H
[Cardiologic findings in newly manifested type II diabetics of the diabetes intervention study]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1986;41(9):256-60.
1985: Fischer S; Hanefeld M; Weck M; Beckert H; Julius U; Eichhorn D; Rothe G; Leonhardt W; Graeser K; Haller H
[Results of protein-sparing modified fasting in hyperlipoproteinemias]
Deutsche Zeitschrift für Verdauungs- und Stoffwechselkrankheiten 1985;45(5):228-35.
1985: Hanefeld M; Schulze J; Fischer S; Julius U; Schmechel H; Haller H
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results.
Monographs on atherosclerosis 1985;13():98-103.
1984: Hanefeld M; Hora C; Schulze J; Rothe G; Barthel U; Haller H
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Atherosclerosis 1984;53(1):47-58.
1984: Honigmann G; Schimke E; Schliack V; Beitz J; Förster W; Fischer S; Hora C; Hanefeld M
Fatty acid composition and action of serum lipoproteins on the PGI2-formation after various oil diets in hyperlipoproteinemia.
Biomedica biochimica acta 1984;43(8-9):S443-6.
1984: Fischer S; Honigmann G; Hora C; Schimke E; Beitz J; Hanefeld M; Leonhardt W; Haller H; Förster W; Schliack V
[Results of linseed oil and olive oil therapy in hyperlipoproteinemia patients]
Deutsche Zeitschrift für Verdauungs- und Stoffwechselkrankheiten 1984;44(5):245-51.
1982: Hora C; Hanefeld M; Leonhardt W; Jacob F; Haller H
[The relation between lipoprotein fractions, sex and IHD in patients with primary hyperlipoproteinemia]
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1982;37(23):801-4.
1981: Weck M; Hanefeld M; Zschornack M; Fischer S; Hora C
[Physical training in obesity]
Zeitschrift für ärztliche Fortbildung 1981;75(23):1103-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Markolf Hanefeld

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Activities & Behaviors

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Markolf Hanefeld (preview)

All Publications